Profound Medical Gears Up for Stifel 2024 Healthcare Conference
Profound Medical Corp. (NASDAQ: PROF; TSX: PRN), a leader in the medical device industry, is preparing to present its latest advancements at the annual Stifel 2024 Healthcare Conference. The event, known for showcasing innovative healthcare technologies, will take place in New York City. Profound’s management is set to deliver a detailed update about the company's initiatives and cutting-edge therapies.
Understanding Profound Medical's Offerings
Profound Medical specializes in developing customizable, incision-free therapies aimed at treating diseased tissue. Their flagship technology, TULSA-PRO, exemplifies the company's commitment to innovation. TULSA-PRO integrates real-time MRI with robotically-driven transurethral ultrasound, representing a remarkable shift in prostate disease treatment. This system not only focuses on precision but also ensures that patients' quality of life is preserved throughout the treatment process.
The TULSA Procedure Explained
The TULSA procedure employs a unique method that allows for pixel-by-pixel targeting, enabling clinicians to effectively destroy unhealthy prostate tissue while maintaining urinary continence and sexual function in patients. This procedure is revolutionizing the approach to prostate cancer, making it a viable option for various risk levels and even for patients with benign prostatic hyperplasia (BPH). By utilizing non-invasive methods, Profound Medical provides a single-session treatment that minimizes recovery times and hospital stays, making it an appealing choice for patients.
Regulatory Approvals and Market Expansion
Not only is the TULSA-PRO system cleared by the FDA, but it also has received CE marking and Health Canada approval, confirming its safety and effectiveness across multiple markets. The company continues to expand its footprint, actively seeking to introduce its technologies to additional international markets.
Introducing Sonalleve for Broader Applications
In addition to TULSA-PRO, Profound Medical is commercializing Sonalleve, a therapeutic platform designed for treating uterine fibroids and managing bone pain from metastases. This versatile tool has gained CE marking and has been recognized by the China National Medical Products Administration, highlighting its efficacy in non-invasive treatments. Furthermore, thanks to its Humanitarian Device Exemption from the FDA, Sonalleve is making strides in clinical applications beyond its initial scope, including potential for treatment of abdominal cancers.
Staying Connected with Profound Medical
As Profound Medical prepares for its presentation at the Stifel 2024 Healthcare Conference, the company emphasizes its commitment to providing detailed information about its technological innovations and potential applications. Stakeholders and interested parties can find more details through Profound's official website under the investors' section.
Contact Information and Further Inquiries
For those looking to learn more or to connect directly with the company, Stephen Kilmer from Investor Relations is available for inquiries. Interested individuals can reach him via email or phone for any additional insights into the company's future and ongoing projects.
Frequently Asked Questions
What is Profound Medical known for?
Profound Medical is known for its innovative, incision-free therapies for treating tissue diseases, particularly through advanced technologies like TULSA-PRO.
When will Profound Medical present at the Stifel Conference?
Profound Medical will present on November 19, 2024, at the Stifel 2024 Healthcare Conference at 9:45 a.m. Eastern Time.
What technologies does Profound Medical offer?
Profound Medical offers TULSA-PRO and Sonalleve, both of which are innovative medical devices designed for treating prostate conditions and uterine fibroids, respectively.
How does the TULSA procedure work?
The TULSA procedure utilizes real-time MRI and ultrasound technology to destroy unhealthy prostate tissue while preserving surrounding healthy tissue.
Who can I contact for more information about Profound Medical?
For further inquiries, Stephen Kilmer, Investor Relations at Profound Medical, can be contacted at 647.872.4849 or via email.
